Why the study?
Patients with myocardial infarction and atrial fibrillation represent a growing highest risk group requiring special clinical attention.
This review highlights the mechanisms, prediction, and antithrombotic therapy considerations for patients with concurrent atrial fibrillation and myocardial infarction, including diagnostic criteria for AF-associated embologenic MIs.
May inform antithrombotic choices in MI-AF overlap; leaves open validation of embologenic MI criteria.
Prevalence of patients with myocardial infarction (MI) and atrial fibrillation (AF) has been growing every year. These patients represent a highest risk group and, thus, require special attention of clinicians. The article foсused on mechanisms of the AF and MI interaction, special aspects of prediction depending on the type of AF and MI, and the issue of antithrombotic therapy in this patient category. A group of AF-associated, embologenic MIs was isolated, and diagnostic criteria and therapeutic regimens were provided.
No takes yet. Share an insight, caveat, or question.
Болдуева et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: